ScripNuvation is transitioning into a commercial-stage biopharma with the launch of Ibtrozi (taletrectinib) for the treatment of ROS1-positive non-small cell lung cancer (NSCLC), where it will compete agai
ScripRiding high on the wave of its dual GIP/GLP-1 agonist, tirzepatide, Eli Lilly awarded its CEO the highest total remuneration package of the top 12 big pharma companies in 2024. David Ricks’s total com
ScripGilead Sciences division Kite is aiming for its bicistronic anti-CD19/CD20 CAR-T therapy KITE-363 to be able to both tamp down toxicity in patients with B-cell lymphomas and to prevent CD19-negative r
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Lilly Will Try Camurus’s FluidCrystal D